Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash & Equivalents (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Cash & Equivalents for 4 consecutive years, with $18.3 million as the latest value for Q1 2025.

  • On a quarterly basis, Cash & Equivalents changed N/A to $18.3 million in Q1 2025 year-over-year; TTM through Mar 2025 was $18.3 million, a N/A change, with the full-year FY2024 number at $22.3 million, down 73.7% from a year prior.
  • Cash & Equivalents was $18.3 million for Q1 2025 at Orchestra BioMed Holdings, down from $22.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $84.6 million in Q4 2023 to a low of $735217.0 in Q3 2022.
  • A 4-year average of $23.4 million and a median of $18.9 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 2494.88% in 2023, then plummeted 73.7% in 2024.
  • Orchestra BioMed Holdings' Cash & Equivalents stood at $19.8 million in 2022, then surged by 327.76% to $84.6 million in 2023, then plummeted by 73.7% to $22.3 million in 2024, then dropped by 17.58% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Cash & Equivalents are $18.3 million (Q1 2025), $22.3 million (Q4 2024), and $54.6 million (Q3 2024).